tradingkey.logo
搜索

Myriad Genetics Inc

MYGN
添加自选
4.250USD
0.0000.00%
收盘 06/16, 16:00美东报价延迟15分钟
401.20M总市值
亏损市盈率 TTM

关于 Myriad Genetics Inc 公司

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Myriad Genetics Inc简介

公司代码MYGN
公司名称Myriad Genetics Inc
上市日期Oct 06, 1995
CEORaha (Samraat S)
员工数量2700
证券类型Ordinary Share
年结日Oct 06
公司地址322 North 2200 West
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编84116
电话18015843600
网址https://myriad.com/
公司代码MYGN
上市日期Oct 06, 1995
CEORaha (Samraat S)

Myriad Genetics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
59.05K
+8.47%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
21.32K
-1299.87%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Heiner Dreismann, Ph.D.
Dr. Heiner Dreismann, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
93.72K
-36.29%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
86.18K
-135.01%

常见问题

Myriad Genetics Inc的前五大股东是谁?

Myriad Genetics Inc 的前五大股东如下:Mr. Mark S. Verratti

有多少机构持有Myriad Genetics Inc(MYGN)的股份?

截至2026Q1,共有539家机构持有Myriad Genetics Inc的股份,合计持有的股份价值约为102.95M,占公司总股份的109.00%。与2025Q4相比,机构持股有所增加,增幅为-7290509.00。

哪个业务部门对Myriad Genetics Inc的收入贡献最大?

在2026Q1,Hereditary Cancer业务部门对Myriad Genetics Inc的收入贡献最大,创收372.40M,占总收入的45.17%。
KeyAI